Early initiation of zidovudine therapy offers a benefit that decreases over time. Symptomatic patients experience a larger benefit than asymptomatic patients. The implications beyond 3 years of follow-up remain unknown.
Estella Matutes, Graham P. Taylor, James D. Cavenagh, Antonio Pagliuca, D. Bareford, Antònia Domingo‐Salvany, Michael R Hamblin, S. Kelsey, N. Mir, John T. Reilly
Discussion(0)
No comments yet. Be the first to comment.